Pharmacokinetics and pharmacodynamics of famotidine in infants. 1998

L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
University of Arkansas for Medical Sciences and Arkansas Children's Hospital, 800 Marshall Street, Little Rock, AR 72202, USA.

The pharmacokinetics and pharmacodynamics of intravenous famotidine were evaluated in 10 infants ranging from 5 to 19 days of age who had a therapeutic indication for the prophylactic treatment of stress ulceration. After a 0.5-mg/kg infusion of famotidine, timed serum (n = 6), urine (24-hour collection), and repeated measurements of gastric pH were obtained. The mean +/- standard deviation maximum plasma concentration (Cmax) was 640.66 +/- 250.66 ng/mL, the elimination half-life (t1/2 beta) was 10.51 +/- 5.43 hours, and the apparent volume of distribution at steady state (Vdss) was 0.82 +/- 0.29 L/kg. Plasma clearance (Cl) and renal clearance (ClR) were 0.132 +/- 0.061 L/hr/kg and 0.093 +/- 0.056 L/hr/kg, respectively. No significant correlations were found between t1/2 beta, Vdss, Cl, and ClR and age. Six of the nine infants who had intragastric pH monitoring maintained a gastric pH > 4 until the final 24-hour sampling point. In this study, the t1/2 beta of famotidine was prolonged and the Vdss, Cl, ClR were reduced compared with corresponding parameters in previously reported studies of children older than one year of age and adults.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D005260 Female Females
D005745 Gastric Acidity Determination Gastric analysis for determination of free acid or total acid. Acidity Determination, Gastric,Acidity Determinations, Gastric,Determination, Gastric Acidity,Determinations, Gastric Acidity,Gastric Acidity Determinations
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015738 Famotidine A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. Famotidine Hydrochloride,MK-208,Pepcid,YM-11170,MK 208,MK208,YM 11170,YM11170

Related Publications

L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
January 1996, Journal of clinical pharmacology,
L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
August 1996, Clinical pharmacokinetics,
L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
January 2005, Clinical pharmacokinetics,
L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
October 1994, Therapeutic drug monitoring,
L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
January 1993, European journal of clinical pharmacology,
L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
February 2014, Journal of clinical pharmacology,
L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
October 1986, The American journal of medicine,
L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
February 1992, British journal of clinical pharmacology,
L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
March 1997, Clinical pharmacology and therapeutics,
L P James, and T Marotti, and C D Stowe, and H C Farrar, and B J Taylor, and G L Kearns
July 1990, Anesthesiology,
Copied contents to your clipboard!